HealthEquity Inc (HQY) Stock
Key stats
- Market cap
- $7.61B
- Price / Earnings ratio
- 32.4x
- EPS (TTM)
- $1.12
- Volume
- Loading
- 52-week high
- $107.62
- 52-week low
- $72.76
Source: third-party data provider, as of October 18, 2026
Compare with HQY
Recent news
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
HQY
Here's Why HealthEquity (HQY) is a Strong Growth Stock
Here's Why HealthEquity (HQY) is a Strong Growth Stock
HQY
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY
HQY Up 15.7% in 3 Months as HSA Growth Builds: Can the Rally Continue?
HQY Up 15.7% in 3 Months as HSA Growth Builds: Can the Rally Continue?
HQYNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.45
- MACD 12/26/9
- -0.95
- EMA 9 of MACD
- -1.43
- MACD histogram
- 0.48
- SMA 50
- $96.25
- Price below SMA 50
- EMA 50
- $93.75
- Price below EMA 50
- SMA 200
- $88.58
- Price above SMA 200
- EMA 200
- $91.48
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 16, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.01 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
HQYHere's Why HealthEquity (HQY) is a Strong Growth Stock
Here's Why HealthEquity (HQY) is a Strong Growth Stock
HQYReasons to Hold HealthEquity Stock in Your Portfolio for Now
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQYHQY Up 15.7% in 3 Months as HSA Growth Builds: Can the Rally Continue?
HQY Up 15.7% in 3 Months as HSA Growth Builds: Can the Rally Continue?
HQY
Here's Why HealthEquity (HQY) is a Strong Growth Stock
Here's Why HealthEquity (HQY) is a Strong Growth Stock
HQY
Why HealthEquity Stock Sank This Week
Why HealthEquity Stock Sank This Week
HQY
HealthEquity Q2 Earnings Call Highlights
HealthEquity Q2 Earnings Call Highlights
HQY
HealthEquity (HQY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
HealthEquity (HQY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
HQY
HealthEquity (HQY) Q2 Earnings and Revenues Top Estimates
HealthEquity (HQY) Q2 Earnings and Revenues Top Estimates
HQY
Ahead of HealthEquity (HQY) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Ahead of HealthEquity (HQY) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
HQYNews tone: automated (AI) classification of the article's content, not a price prediction.
About HealthEquity Inc
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Scott R. Cutler J.D. | CEO, President & Director | 1970 |
| Mr. James M. Lucania | CFO & Executive VP | 1979 |
| Dr. Stephen D. Neeleman M.D. | Founder & Vice Chairman | 1968 |
| Mr. Delano Ladd J.D. | Executive VP, General Counsel & Secretary | 1981 |
| Mr. Richard Putnam | Vice President of Investor Relations | — |
| Ms. Stacey Ullrich | Senior Vice President of Corporate Communications | — |
| Mr. Steve Lindsay | Executive Vice President of Sales & Relationship Management | — |
| Mr. Brad Bennion | Executive Vice President of Corporate Development & Strategy | — |
| Mr. Mukund Ramachandran | Chief Marketing Officer | — |
| Ms. Cheryl King | Executive VP & Chief People Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 18, 2026
Technical indicators
- RSI 14
- 48.45
- MACD 12/26/9
- -0.95
- EMA 9 of MACD
- -1.43
- MACD histogram
- 0.48
- SMA 50
- $96.25
- Price below SMA 50
- EMA 50
- $93.75
- Price below EMA 50
- SMA 200
- $88.58
- Price above SMA 200
- EMA 200
- $91.48
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 16, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $115.00
- Average
- $124.00
- High
- $142.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.0 | -19.8 | -18.8 | |||||||||
| 2022 | +14.1 | +0.2 | +28.6 | -7.5 | -2.1 | -1.3 | +0.9 | +15.8 | +2.2 | +15.2 | -19.1 | -2.6 |
| 2023 | +0.2 | +10.5 | -10.2 | -6.8 | +1.4 | +13.5 | +8.9 | -0.0 | +10.0 | -2.9 | -1.6 | -4.5 |
| 2024 | +14.2 | +9.2 | +0.7 | -3.3 | +2.4 | +6.1 | -9.4 | +2.2 | +4.1 | +6.2 | +17.6 | -5.6 |
| 2025 | +14.1 | -0.5 | -15.7 | -1.5 | +14.4 | +1.9 | -5.7 | -1.9 | +6.7 | +4.3 | +10.9 | -10.5 |
| 2026 | -5.9 | -12.2 | +7.2 | -1.6 | +6.8 | -0.4 | +9.0 | -7.5 | -8.8 | +3.0 |
